Population Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2016 Mar 22

PMID 26998818

Citations 167

Authors

Oxana V Makarova-Rusher

Sean F Altekruse

Tim S McNeel

Susanna Ulahannan

Austin G Duffy

Barry I Graubard

Tim F Greten

Katherine A McGlynn

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) incidence has been increasing in the United States for several decades; and, as the incidence of hepatitis C virus (HCV) infection declines and the prevalence of metabolic disorders rises, the proportion of HCC attributable to various risk factors may be changing.

Methods: Data from the Surveillance, Epidemiology, and End Results-Medicare linkage were used to calculate population attributable fractions (PAFs) for each risk factor over time. Patients with HCC (n = 10,708) who were diagnosed during the years 2000 through 2011 were compared with a 5% random sample of cancer-free controls (n = 332,107) residing in the Surveillance, Epidemiology, and End Results areas. Adjusted odds ratios (ORs) and PAFs were calculated for HCV, hepatitis B virus (HBV), metabolic disorders, alcohol-related disorders, smoking, and genetic disorders.

Results: Overall, the PAF was greatest for metabolic disorders (32%), followed by HCV (20.5%), alcohol (13.4%), smoking (9%), HBV (4.3%), and genetic disorders (1.5%). The PAF for all factors combined was 59.5%. PAFs differed by race/ethnicity and sex. Metabolic disorders had the largest PAF among Hispanics (PAF, 39.3%; 95% confidence interval [CI], 31.9%-46.7%) and whites (PAF, 34.8%; 95% CI, 33.1%-36.5%), whereas HCV had the largest PAF among blacks (PAF, 36.1%; 95% CI, 31.8%-40.4%) and Asians (PAF, 29.7%; 95% CI, 25.9%-33.4%). Between 2000 and 2011, the PAF of metabolic disorders increased from 25.8% (95% CI, 22.8%-28.9%) to 36% (95% CI, 33.6%-38.5%). In contrast, the PAFs of alcohol-related disorders and HCV remained stable.

Conclusions: Among US Medicare recipients, metabolic disorders contribute more to the burden of HCC than any other risk factor, and the fraction of HCC caused by metabolic disorders has increased in the last decade. Cancer 2016;122:1757-65. Published 2016. This article is a U.S. Government work and is in the public domain in the USA..

Citing Articles

County-Level Food Insecurity and Hepatocellular Carcinoma Risk: A Cross-Sectional Analysis.

Kehm R, Vilfranc C, McDonald J, Wu H Int J Environ Res Public Health. 2025; 22(1).

PMID: 39857573 PMC: 11765400. DOI: 10.3390/ijerph22010120.

Environmental exposures and the risk of hepatocellular carcinoma.

Rayapati D, McGlynn K, Groopman J, Kim A Hepatol Commun. 2025; 9(2.

PMID: 39813595 PMC: 11737496. DOI: 10.1097/HC9.0000000000000627.

Hepatitis C virus attributable liver cancer in the country of Georgia, 2015-2019: a case-control study.

Surguladze S, Armstrong P, Beckett G, Shadaker S, Gamkrelidze A, Tsereteli M BMC Infect Dis. 2024; 24(1):1045.

PMID: 39333949 PMC: 11429595. DOI: 10.1186/s12879-024-09916-7.

Hepatocellular Carcinoma Etiology Drives Survival Outcomes: A Population-Based Analysis.

Cranford H, Jones P, Wong R, Liu Q, Kobetz E, Reis I Cancer Epidemiol Biomarkers Prev. 2024; 33(12):1717-1726.

PMID: 39240221 PMC: 11611647. DOI: 10.1158/1055-9965.EPI-24-0626.

Ultra-processed products and risk of liver cancer: A prospective cohort study.

Zhao L, Zhang X, Yu D, Wang L, Shrubsole M, Zheng W Clin Nutr. 2024; 43(10):2298-2304.

PMID: 39226717 PMC: 11479389. DOI: 10.1016/j.clnu.2024.08.011.

References

Welzel T, Graubard B, Zeuzem S, El-Serag H, Davila J, McGlynn K . Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011; 54(2):463-71. PMC: 4141525. DOI: 10.1002/hep.24397. View

Beltran-Sanchez H, Harhay M, Harhay M, McElligott S . Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol. 2013; 62(8):697-703. PMC: 3756561. DOI: 10.1016/j.jacc.2013.05.064. View

Baffy G, Brunt E, Caldwell S . Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012; 56(6):1384-91. DOI: 10.1016/j.jhep.2011.10.027. View

McQuillan G, Kruszon-Moran D, Kottiri B, Curtin L, Lucas J, Kington R . Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994. Am J Public Health. 2004; 94(11):1952-8. PMC: 1448568. DOI: 10.2105/ajph.94.11.1952. View

Braga C, La Vecchia C, Negri E, Franceschi S . Attributable risks for hepatocellular carcinoma in northern Italy. Eur J Cancer. 1997; 33(4):629-34. DOI: 10.1016/s0959-8049(96)00500-x. View

Lang E, Schafer M, Schwender H, Neumann N, Frank J . Occurrence of Malignant Tumours in the Acute Hepatic Porphyrias. JIMD Rep. 2015; 22:17-22. PMC: 4486276. DOI: 10.1007/8904_2015_406. View

Dragani T . Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2009; 52(2):252-7. DOI: 10.1016/j.jhep.2009.11.015. View

Parkin D, Bray F, Ferlay J, Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2):153-6. DOI: 10.1002/ijc.1440. View

Altekruse S, Henley S, Cucinelli J, McGlynn K . Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014; 109(4):542-53. PMC: 4148914. DOI: 10.1038/ajg.2014.11. View

10.

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

11.

Fracanzani A, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A . Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001; 33(3):647-51. DOI: 10.1053/jhep.2001.22506. View

12.

Altekruse S, McGlynn K, Reichman M . Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009; 27(9):1485-91. PMC: 2668555. DOI: 10.1200/JCO.2008.20.7753. View

13.

Ertle J, Dechene A, Sowa J, Penndorf V, Herzer K, Kaiser G . Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2010; 128(10):2436-43. DOI: 10.1002/ijc.25797. View

14.

Ng M, Freeman M, Fleming T, Robinson M, Dwyer-Lindgren L, Thomson B . Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014; 311(2):183-92. DOI: 10.1001/jama.2013.284692. View

15.

Warren J, Klabunde C, Schrag D, Bach P, Riley G . Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40(8 Suppl):IV-3-18. DOI: 10.1097/01.MLR.0000020942.47004.03. View

16.

Hassan M, Hwang L, Hatten C, Swaim M, Li D, Abbruzzese J . Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002; 36(5):1206-13. DOI: 10.1053/jhep.2002.36780. View

17.

Mannino D, Buist A . Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370(9589):765-73. DOI: 10.1016/S0140-6736(07)61380-4. View

18.

Ott J, Stevens G, Groeger J, Wiersma S . Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12):2212-9. DOI: 10.1016/j.vaccine.2011.12.116. View

19.

Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C . The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol. 2008; 20(2):353-7. DOI: 10.1093/annonc/mdn565. View

20.

Polesel J, Montella M, Dal Maso L, Crispo A, Serraino D, Talamini R . Re: hepatocellular carcinoma risk factors and disease burden in a european cohort: a nested case-control study. J Natl Cancer Inst. 2012; 104(21):1681-3. DOI: 10.1093/jnci/djs379. View